2017
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials
Le-Rademacher J, Kanwar R, Seisler D, Pachman D, Qin R, Abyzov A, Ruddy K, Banck M, Lavoie Smith E, Dorsey S, Aaronson N, Sloan J, Loprinzi C, Beutler A. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Supportive Care In Cancer 2017, 25: 3537-3544. PMID: 28634656, PMCID: PMC5693734, DOI: 10.1007/s00520-017-3780-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarboplatinFemaleHumansMaleMiddle AgedNeoplasmsOrganoplatinum CompoundsOxaliplatinPaclitaxelPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPhysiciansConceptsChemotherapy-induced peripheral neuropathyCTCAE gradePatient-reported outcomesQLQ-CIPN20Peripheral neuropathyClinical trialsNCI Common Terminology CriteriaCommon Terminology CriteriaMultivariable linear mixed modelsRecent clinical trialsTerminology CriteriaAdverse eventsCancer QualityClinical caveatsSerial assessmentClinical trial datasetPractice guidelinesIndividual patientsEuropean OrganizationCTCAEPatientsOutcome variablesStrong positive associationLinear mixed modelsNeuropathy
2016
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
Boora G, Kanwar R, Kulkarni A, Abyzov A, Sloan J, Ruddy K, Banck M, Loprinzi C, Beutler A. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Medicine 2016, 5: 631-639. PMID: 26763541, PMCID: PMC4831281, DOI: 10.1002/cam4.625.Peer-Reviewed Original ResearchConceptsPaclitaxel-induced peripheral neuropathyProtective effectAdditional clinical cohortsSingle nucleotide variantsPrevious reportsGene CYP2C8Pharmacogenomic basisPeripheral neuropathyClinical parametersOdds ratioClinical cohortNucleotide variantsCandidate single nucleotide variantsMultiple studiesHigher likelihoodTaqMan PCRCYP2C8AssociationSequencing analysisRisk effectsSubset of findingsReportNeuropathyPrevious studiesPatients